Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma

Isatuximab elicits antitumor activity via multiple tumor-targeting pathways. The direct cytotoxic mechanism of isatuximab is a key differentiator from other anti-CD38 antibodies and translates into clinical benefits in patients with MM. Isatuximab only relies partly on complement-dependent cytotoxicity activity for its anti-tumor activity, which may have beneficial prognostic implications for patients with 1q21 chromosomal abnormalities and extramedullary disease. This is supported by clinical data, which demonstrate a favorable benefit/risk profile in MM patients including difficult-to-treat patients with poor prognostic outcomes. Further, addition of the novel on-body injector to isatuximab administration modalities may provide advantages over current administration methods.